bioMérieux S.A. provided sales guidance for the first half and full year of 2021. For the first half, sales are now expected to grow at around 10% at constant exchange rates and scope of consolidation. In an unpredictable environment, which contracted evolution of the pandemic, full year sales are now expected to grow organically at neutral to mid-single digit rates and annual guidance for contributive operating income is maintained.